🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Relapsing Multiple Sclerosis

Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis NCT06389968NA1 site📍 Munich Technical University of Munich · Tests: Light stimulation, Sham light stimulation A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis NCT07189325Phase 31 site📍 Montpellier University Hospital, Montpellier · Tests: Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons), Anti-CD20 therapies (Ocrel… Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels NCT07353216n/a1 site📍 Guangzhou Third Affiliated Hospital, Sun Yat-Sen University · Tests: Ofatumumab A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis NCT06138132Phase 11 site📍 Palo Alto Stanford University · Tests: KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen Home Based Functional Balance Intervention for Multiple Sclerosis NCT07355387NA1 site📍 Chicago University of Illinois at Chicago · Tests: Multicomponent balance intervention consisting of four components including dual-tasking, functional strength, vestibul… A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) NCT06433752n/a111 sites📍 Birmingham📍 Cullman📍 Huntsville TG Therapeutics, Inc. · Tests: No Intervention Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis NCT07220252Phase 2, Phase 33 sites📍 Gdansk📍 Poznan📍 Warsaw TG Therapeutics, Inc. · Tests: Ublituximab, Placebo, Placebo, Fingolimod Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases NCT06939166EARLY Phase 11 site📍 Tianjin Tianjin Huanhu Hospital · Tests: UCAR T-cell ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS NCT06733922Phase 414 sites📍 Calgary📍 Calgary📍 Edmonton Novartis Pharmaceuticals · Tests: ETNATM-ProgMS Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. NCT06846281Phase 3131 sites📍 Scottsdale📍 Irvine📍 Washington D.C. Novartis Pharmaceuticals · Tests: Remibrutinib oral treatment, Ocrelizumab Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND) NCT07360977NA1 site📍 Messina IRCCS Centro Neurolesi Bonino Pulejo · Tests: bioactivated GRA for adult patients, bioactivated GRA for pediatric patients Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis NCT03401879NA1 site📍 Vienna Medical University of Vienna · Tests: Dynamic Vessel Analyzer (DVA), Fourier Domain Doppler Optical Coherence Tomography (FDOCT), Optical coherence tomograph… Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation in the Netherlands NCT06567197n/a2 sites📍 Amsterdam📍 Nieuwegein Amsterdam UMC, location VUmc A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy NCT07609719Phase 45 sites📍 Scottsdale📍 Maitland📍 Atlanta Genentech, Inc. · Tests: OCR SC Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) NCT04047628Phase 323 sites📍 Palo Alto📍 Aurora📍 Evanston National Institute of Allergy and Infectious Diseases (NIAI… · Tests: Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT) Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic NCT05962177NA1 site📍 Montpellier University Hospital, Montpellier · Tests: Magnetic Resonance Imaging, Blood withdrawal, Neuropsychological tests REtinal Markers In Neuroinflammatory Diseases ("REMIND") NCT06369766n/a1 site📍 Basel University Hospital, Basel, Switzerland · Tests: Optical coherence tomography (OCT), Static retinal vessel analyzer, Dynamic retinal vessel analyzer, Laser speckle flow… Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis NCT07318129NA1 site📍 Glostrup Municipality Glostrup University Hospital, Copenhagen · Tests: Placebo, Indole-3-propionic acid (IPA) Identifying Immune Biomarkers of Disease and Disease Control in Autoimmune Neurological Disease Using Autologous Haematopoietic Stem Cell Transplantation NCT06195800n/a1 site📍 Sheffield Sheffield Teaching Hospitals NHS Foundation Trust Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis NCT06919900NA1 site📍 Atlanta Georgia State University · Tests: Perturbation Training, Treadmill Walking Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS NCT05834855Phase 31 site📍 Amsterdam Amsterdam UMC, location VUmc · Tests: Rituximab A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis NCT07321093Phase 31 site📍 Nizhny Novgorod Biocad · Tests: BCD-281, Ocrelizumab Sexual Dysfunction in Women With Multiple Sclerosis (MS) NCT07193823n/a1 site📍 Izmir Ege University Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis NCT07426991n/a2 sites📍 Düsseldorf📍 Mönchengladbach Heinrich-Heine University, Duesseldorf · Tests: No Intervention: Observational Cohort Investigation of Subclinical Markers of Multiple Sclerosis NCT04604041n/a1 site📍 Split University of Split, School of Medicine · Tests: 1. Clinical testing; 2. Neurophysiological examination (TMS, EMNG); 3. Psychomotor examination; 4. Neuropsychological e… Fatigue Alleviation Through Neuromodulating Therapy in Multiple Sclerosis NCT06569550NA1 site📍 Hvidovre Danish Research Centre for Magnetic Resonance · Tests: Real Repetitive Transcranial Magnetic Stimulation, Sham Repetitive Transcranial Magnetic Stimulation Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study NCT06486779n/a15 sites📍 Athens📍 Athens📍 Alexandroupoli Novartis Pharmaceuticals · Tests: Ofatumumab "Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS NCT07222618n/a1 site📍 San Francisco University of California, San Francisco Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy NCT05359653Phase 1, Phase 21 site📍 San Francisco University of California, San Francisco · Tests: Clemastine Fumarate, Placebo Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation NCT05958381NA1 site📍 Richardson The University of Texas at Dallas · Tests: Transcranial Direct Current Stimulation, Sham transcranial direct current stimulation
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy